These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12773258)

  • 1. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
    Boland A; Dundar Y; Bagust A; Haycox A; Hill R; Mujica Mota R; Walley T; Dickson R
    Health Technol Assess; 2003; 7(15):1-136. PubMed ID: 12773258
    [No Abstract]   [Full Text] [Related]  

  • 2. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 4. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.
    Giraldez RR; Wiviott SD; Nicolau JC; Mohanavelu S; Morrow DA; Antman EM; Giugliano RP
    Drugs; 2009 Jul; 69(11):1433-43. PubMed ID: 19634922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review.
    Dundar Y; Hill R; Dickson R; Walley T
    QJM; 2003 Feb; 96(2):103-13. PubMed ID: 12589008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian cost-effectiveness analysis. An example using the GUSTO trial.
    Fryback DG; Chinnis JO; Ulvila JW
    Int J Technol Assess Health Care; 2001; 17(1):83-97. PubMed ID: 11329847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic lessons from studies of coronary thrombolysis.
    Mark DB
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):94S-101S. PubMed ID: 8770850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenecteplase: single-bolus thrombolytic therapy for acute myocardial infarction.
    McGahan L
    Issues Emerg Health Technol; 2001 Jan; (13):1-6. PubMed ID: 11902221
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 10. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction.
    El-Menyar AA; Altamimi OM; Gomaa MM; Dabdoob W; Abbas AA; Abdel Rahman MO; Bener A; Albinali HA
    Coron Artery Dis; 2006 Aug; 17(5):431-7. PubMed ID: 16845251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of acute myocardial infarction in Switzerland: is emergency PTCA more costly than thrombolysis?].
    Hagmann A; Amann W; Urban P; Pfisterer M
    Schweiz Med Wochenschr; 1999 Oct; 129(39):1389-96. PubMed ID: 10542996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic therapy in acute myocardial infarction.
    Hampton JR
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():241-6. PubMed ID: 9211016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial infarction, thrombolytic therapy, and economics.
    Shander D
    Clin Cardiol; 1993 Nov; 16(11):845. PubMed ID: 8269667
    [No Abstract]   [Full Text] [Related]  

  • 15. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergent decision-making: defining the patient perspective.
    Knudtson ML
    Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261
    [No Abstract]   [Full Text] [Related]  

  • 17. Interpreting results from thrombolytic megatrials: distinguishing fact from fiction.
    Brophy JM
    Can J Cardiol; 1996 Jan; 12(1):89-92. PubMed ID: 8595575
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece.
    Maniadakis N; Kaitelidou D; Siskou O; Spinthouri M; Liaropoulos L; Fragoulakis B; Hatzikou M; Alexopoulosi D
    Hellenic J Cardiol; 2005; 46(3):212-21. PubMed ID: 15981557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in thrombolytic therapy for acute myocardial infarction.
    Topol EJ
    J Clin Pharmacol; 1987 Oct; 27(10):735-45. PubMed ID: 3123526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
    Collen D
    Ann Intern Med; 1990 Apr; 112(7):529-38. PubMed ID: 2107781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.